In a patient with a history of cancer treated with multiple courses of radiation and chemotherapy who now has a normal left ventricular ejection fraction (~59%) but moderately reduced global longitudinal strain (~‑12%) and otherwise normal cardiac function, what is the next best step in cardiac management?

Initiate ACE Inhibitor or ARB Therapy and Refer to Cardiology

In this patient with cancer treatment history and moderately reduced global longitudinal strain (GLS -11.9%) despite preserved LVEF (59%), you should start an ACE inhibitor (or ARB) and refer to cardiology immediately. This represents subclinical cardiotoxicity—essentially stage B heart failure—requiring intervention to prevent progression to symptomatic heart failure.

Rationale for Immediate Cardioprotective Therapy

Your patient has cancer therapy-related cardiac dysfunction (CTRCD) detected at the subclinical stage. The GLS of -11.9% represents a significant abnormality (normal is ≤-17% to -20%), indicating myocardial injury from prior chemotherapy and radiation despite the "normal" LVEF of 59%. This dissociation between preserved LVEF and reduced GLS is a hallmark of early cardiotoxicity 1.

Why This Matters for Morbidity and Mortality

• CTRCD carries 3.5-fold higher mortality compared to idiopathic cardiomyopathy 2
• Early intervention is critical: When cardioprotective therapy (ACE inhibitors/beta-blockers) is initiated within 6 months of detecting dysfunction, LVEF recovery occurs in 42% of patients. When delayed, recovery is partial or absent 2, 1
• Reduced GLS predicts future LVEF decline: Patients with reduced GLS have significantly higher risk of developing overt cardiac dysfunction 3, 4

Specific Treatment Algorithm

1. Start ACE Inhibitor Immediately 5, 6, 1

Choose one of these evidence-based regimens:

• Enalapril: Start 2.5 mg once daily, titrate to 20 mg once daily (maximum 10-20 mg twice daily) 5
• Lisinopril: Start 2.5 mg once daily, titrate to 20 mg once daily (maximum 35 mg once daily) 5
• Ramipril: Start 1.25 mg once daily, titrate to 2.5-5 mg once daily (maximum 10 mg once daily) 5

Alternative if ACE inhibitor not tolerated: ARB (e.g., candesartan) 1

2. Consider Adding Beta-Blocker 2, 1

Strong evidence supports combination therapy:

• Carvedilol (preferred): Start 6.25-12.5 mg twice daily, titrate to 25-50 mg twice daily 2
• Nebivolol: Alternative with demonstrated cardioprotection 2
• Avoid propranolol (may be cardiotoxic) and metoprolol (neutral effect) 2

Combined ACE inhibitor + beta-blocker therapy shows greater LVEF recovery than ACE inhibitor alone 2, 1

3. Cardiology Referral 5, 6, 1

Refer to cardio-oncology specialist (or general cardiologist if unavailable) for:

• Optimization of heart failure medications
• Assessment for additional cardioprotective strategies
• Surveillance planning
• Risk stratification for future cardiac events

4. Surveillance Strategy 6, 7, 2

Repeat echocardiography in 3 months to assess:

• LVEF response to therapy
• GLS improvement (target improvement toward normal)
• Development of symptoms

Measure cardiac biomarkers (if not already done):

• Troponin I or T: Elevation indicates ongoing myocardial injury 6, 1
• BNP or NT-proBNP: Elevation suggests hemodynamic stress 6, 1

If biomarkers elevated, consider monthly monitoring 6

Critical Pitfalls to Avoid

Don't Wait for LVEF to Drop

The LVEF is still "normal" at 59%, but GLS detects dysfunction 1-3 months earlier than LVEF 8. Waiting for LVEF decline means missing the window for optimal intervention 2, 1.

Don't Dismiss Moderate Tricuspid Regurgitation

While the focus is on LV dysfunction, the moderate TR warrants monitoring as it may reflect right heart involvement from radiation or chemotherapy effects.

Don't Delay Treatment Pending Cardiology Consultation

You can and should start ACE inhibitor therapy immediately as the primary oncologist or internist 5, 6. The cardiology referral is for optimization and ongoing management, not to delay initial intervention.

Evidence Hierarchy

The most recent and comprehensive guidelines 6, 1 from ESMO (2020) and ESC (2017) consistently recommend:

1. Reduced GLS (>15% relative reduction or absolute value >-17%) = actionable cardiotoxicity requiring intervention even with preserved LVEF
2. ACE inhibitors/ARBs as first-line cardioprotection (Class III, Level A recommendation) 6
3. Beta-blockers as adjunctive therapy with strong supporting evidence 2, 1
4. Early intervention (within 6 months) maximizes recovery potential 2, 1

Additional Considerations

Radiation history requires long-term surveillance as cardiac effects can manifest years later 2. This patient needs:

• Continued annual cardiac imaging
• Aggressive cardiovascular risk factor modification
• Screening for coronary artery disease (radiation increases risk)
• Valvular disease monitoring (radiation-induced)

Quality of Life Impact: Early intervention preserves cardiac function, preventing symptomatic heart failure that would severely impact this cancer survivor's quality of life and potentially limit future cancer treatment options if recurrence occurs 2.